Cystic Fibrosis Flashcards
Pattern of inheritance of Cystic Fibrosis
Autosomal recessive
Major morbidity & Mortality associated with Cystic Fibrosis
Pulmonary Compromise characterized by copious hyperviscous and adherent secretions that obstructs the small and medium sized airways
Bacterial flora routinely cultured from CF sputum
PSH
Pseudomonas aeruginosa
Staphylococcus aureus
Haemophilus influenza
Manifestation of >30% of adults with disease
CF-related diabetes mellitus
Most common genetic abnormality in Cystic Fibrosis
Class II defects: CFTR mutation that disrupt protein maturation
~90% of individuals with CF carry atleast one _____ mutation
F508del mutation
Cardinal Test for Cystic Fibrosis
Sweat Electrolyte Measurements
Mainstay of Diagnosis in patients with CF
Sweat test electrolytes following PILOCARPINE IONTOPHORESIS
First approved compound of CFTR modulator that potentiates mutant CFTR gating and stimulates ion transport
Ivacaftor
MOA: overcomes G551D CFTR gating defect, and individuals carrying this mutation exhibit pronounced improvement of lung function, weight gain. Sweat chloride values are significantly reduced by the drug.
Highly effective Modulator Treatment (HEMTs) for Cystic Fibrosis, which benefits >90% of individuals with the disease. Causes marked enhancement of the FEV1, fewer respiratory exacerbations, improved quality of life and diminished sweat chloride
TRIPLE COMBINATION THERAPY
-Elexacaftor
-Tezacaftor
-Ivacaftor
Drugs administered routinely for Cystic Fibrosis patients
- Recombinant DNAse aerosols (degrade DNA strands that contribute to mucus viscosity)
- Nebulized Hypertonic Saline (serves to augment periciliary fluid layer, activate mucociliary clearance & mobilize inspissated airway secretions
Standard means to promote clearance of airway mucus
Chest physiotherapy several times a day
Poor prognostic indicators of Cystic Fibrosis
Sputum culture containing:
-Burkholderia cepacia complex
-Pseudomonas aeruginosa
-Atypical mycobacteria
-Staphylococcus aureus (may be associated)
Typical inpatient antibiotic coverage for Cystic Fibrosis
Combination drug therapy with an Aminoglycoside + Beta-lactam for at least 14 days
Maximal improvement in lung function after antibiotic therapy
Achieved by 8-10 days
What should be considered in individuals who have absence of favorable response to aggressive inpatient treatment, usually seen in ~5% of individuals with Cystic Fibrosis?
Hypersensitivity to Aspergillus
(allergic bronchopulmonary aspergillosis)
Serves as an anion channel in the apical plasma membranes of the epithelial cells and regulates the volume and composition of exocrine secretion
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
This organism further aggravates respiratory decline. It exhibit a stereotypic mode of pathogenesis
A sentinel and early colonization event often engenders lifelong pulmonary infection by the same genetic strain.
Pseudomonas aeruginosa
Refers to profound tissue destruction of the exocrine pancreas, with fibrotic scarring and/or fatty replacement, cyst formation, loss of acinar tissue, and ablation of normal pancreatic architecture.
Cystic Fibrosis of the Pancreas